肝移植患者中FK 506血浆水平升高与肾毒性的关联。 - Suppr

Suppr

超能文献

Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.

作者信息

Winkler M, Jost U, Ringe B, Gubernatis G, Wonigeit K, Pichlmayr R

机构信息

Klinik für Abdominal- und Transplantationschirurgie Medizinische Hochschule, Hannover, Germany.

出版信息

Transplant Proc. 1991 Dec;23(6):3153-5.

PMID:1721389

Abstract

摘要

相似文献

Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients.肝移植患者中FK 506血浆水平升高与肾毒性的关联。

Transplant Proc. 1991 Dec;23(6):3153-5.

Plasma level-guided low-dose FK 506 therapy in patients with early liver dysfunction after liver transplantation.

Transplant Proc. 1993 Aug;25(4):2688-90.

FK 506 treatment of intractable rejection after liver transplantation.FK506治疗肝移植后难治性排斥反应

Transplant Proc. 1993 Aug;25(4):2686-7.

Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients.FK506和环孢素在肝移植受者中用作初始免疫抑制时的肾毒性。

Transplant Proc. 1993 Feb;25(1 Pt 1):665-8.

Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity.肝移植后FK 506的全血和血浆水平：与毒性的相关性。

Transplant Proc. 1994 Jun;26(3):1804.

Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.FK506 挽救治疗急性肝移植排斥反应后出现反复排斥反应。

Transplant Proc. 1993 Apr;25(2):1988-9.

FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.FK506挽救治疗：排斥反应逆转的速度与随后巨细胞病毒疾病的发生有关。

Transplant Proc. 1993 Apr;25(2):1992-3.

Use of FK 506 for treatment of chronic rejection after liver transplantation.使用FK 506治疗肝移植后的慢性排斥反应。

Transplant Proc. 1991 Dec;23(6):2984-6.

Transplant Proc. 1991 Dec;23(6):3173-4.

FK 506 rescue therapy: early conversion improves efficacy.

Transplant Proc. 1993 Apr;25(2):1990-1.

引用本文的文献

A retrospective analysis of the safety and efficacy of low dose tacrolimus (FK506) for living donor liver transplant recipients.低剂量他克莫司（FK506）用于活体供肝移植受者的安全性和有效性的回顾性分析。

J Biomed Res. 2013 Jul;27(4):305-9. doi: 10.7555/JBR.27.20130023. Epub 2013 Jun 13.

Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.接受含利托那韦增效蛋白酶抑制剂或雷特格韦的 HIV-1 治疗的患者中他克莫司的每日剂量。

J Antimicrob Chemother. 2010 May;65(5):999-1004. doi: 10.1093/jac/dkq054. Epub 2010 Mar 4.

Factors affecting variability in distribution of tacrolimus in liver transplant recipients.影响肝移植受者他克莫司分布变异性的因素。

Br J Clin Pharmacol. 2004 Mar;57(3):298-309. doi: 10.1046/j.1365-2125.2003.02008.x.

Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats.

Pediatr Nephrol. 2003 Sep;18(9):860-4. doi: 10.1007/s00467-003-1196-z. Epub 2003 Jun 26.

Mechanisms of clinically relevant drug interactions associated with tacrolimus.与他克莫司相关的临床显著药物相互作用机制。

Clin Pharmacokinet. 2002;41(11):813-51. doi: 10.2165/00003088-200241110-00003.

Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients.他克莫司全血浓度与肾移植受者的副作用密切相关。

Br J Clin Pharmacol. 1999 Sep;48(3):445-8. doi: 10.1046/j.1365-2125.1999.00007.x.

The use of therapeutic drug monitoring to optimise immunosuppressive therapy.使用治疗药物监测来优化免疫抑制治疗。

Clin Pharmacokinet. 1996 Feb;30(2):107-40. doi: 10.2165/00003088-199630020-00003.

Clinical pharmacokinetics of tacrolimus.他克莫司的临床药代动力学

Clin Pharmacokinet. 1995 Dec;29(6):404-30. doi: 10.2165/00003088-199529060-00003.

A risk-benefit assessment of tacrolimus in transplantation.他克莫司在移植中的风险效益评估。

Drug Saf. 1995 May;12(5):348-57. doi: 10.2165/00002018-199512050-00006.

Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA).采用高效液相色谱-质谱联用（h.p.l.c.-MS）和微粒酶免疫分析法（MEIA）测定7例肝移植患者首次给药后FK506（他克莫司）及其代谢物的血药浓度。

Br J Clin Pharmacol. 1994 Dec;38(6):567-71. doi: 10.1111/j.1365-2125.1994.tb04398.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验